Biovail Corp
Article Abstract:
The Federal Food and Drug Administration recently approved some of its drugs including Biovail Corp.'s Cardizen LA, an extended release formulation of Cardizem, a therapy for hypertension and angina, to be co-marketed with Reliant Pharmaceuticals. Stock price has highest rank for Timeliness and risen 40% and projected to have capital gains potential out to 2006-2008.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2003
User Contributions:
Comment about this article or add new information about this topic:
AMGEN
Article Abstract:
AMGEN Inc.'s revenues are expected to advance 37% in 2002 due to lower research and development costs, new products to be licensed by the FDA. Stock is ranked to outperform the market in 2003 with appreciation potential out to 2006-2008.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2003
User Contributions:
Comment about this article or add new information about this topic: